146 related articles for article (PubMed ID: 25909124)
1. [Ca-125 in diagnosis and monitoring of patients with ovarian cancer].
Bocheva Y; Bochev P; Ivanov S
Akush Ginekol (Sofiia); 2015; 54(1):11-7. PubMed ID: 25909124
[TBL] [Abstract][Full Text] [Related]
2. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
3. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
[TBL] [Abstract][Full Text] [Related]
4. [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker].
Zeimet AG; Guadagni F; Marth C; Amato T; Müller-Holzner E; Huter O; Daxenbichler G; Dapunt O
Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):195-9. PubMed ID: 7789707
[TBL] [Abstract][Full Text] [Related]
5. [Clinical analysis of benign pelvic mass with high serum levels of CA(125)].
Zhang X; Wu LY; Li XJ; Li HJ; Zhang R; Liu LY
Zhonghua Fu Chan Ke Za Zhi; 2005 Mar; 40(3):178-82. PubMed ID: 15840313
[TBL] [Abstract][Full Text] [Related]
6. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
van Dalen A; Favier J; Baumgartner L; Hasholzner U; de Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Einarsson R
Anticancer Res; 1999; 19(4A):2523-6. PubMed ID: 10470187
[TBL] [Abstract][Full Text] [Related]
8. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
9. Abdominal recurrence of ovarian cancer: value of abdominal MR in patients with positive CA125 and negative CT.
Balestreri L; Bison L; Sorio R; Morra A; Campagnutta E; Morassut S
Radiol Med; 2002; 104(5-6):426-36. PubMed ID: 12589264
[TBL] [Abstract][Full Text] [Related]
10. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis.
Sørensen SS; Mosgaard BJ
Dan Med Bull; 2011 Nov; 58(11):A4331. PubMed ID: 22047929
[TBL] [Abstract][Full Text] [Related]
11. [Tumor marker in ovarian cancer].
Komai K; Nishida T
Gan To Kagaku Ryoho; 2002 Mar; 29(3):481-6. PubMed ID: 11915744
[TBL] [Abstract][Full Text] [Related]
12. HE4 in ovarian cancer: from discovery to clinical application.
Montagnana M; Danese E; Giudici S; Franchi M; Guidi GC; Plebani M; Lippi G
Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021
[TBL] [Abstract][Full Text] [Related]
13. [Rising CA-125 levels in a patient with ovarian cancer are not always indicative of disease recurrence].
Yerushalmi R; Rakowsky E; Sulkes A
Harefuah; 2002 Apr; 141(4):347-8, 410. PubMed ID: 12017887
[TBL] [Abstract][Full Text] [Related]
14. One biologic marker (carbohydrate antigen-CA 125), two different diseases (ovarian cancer and congestive heart failure): practical implications of monitoring CA 125 serum levels. A case report.
Faggiano P; D'Aloia A; Bignotti T; Dei Cas L
Ital Heart J; 2003 Jul; 4(7):497-9. PubMed ID: 14558304
[TBL] [Abstract][Full Text] [Related]
15. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumour markers in ovarian tumours.
von Schlippe M; Rustin GJ
Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
[TBL] [Abstract][Full Text] [Related]
17. [Ovarian tumor markers of presumed benign ovarian tumors].
Lahlou N; Brun JL
J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):752-9. PubMed ID: 24210243
[TBL] [Abstract][Full Text] [Related]
18. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
20. [HE4--a new tumor marker for ovarian cancer].
Manolov V; Marinov B; Vasilev V; Andreeva A
Akush Ginekol (Sofiia); 2011; 50 Suppl 2():11-5. PubMed ID: 22524132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
